KB-1103

Ipilimumab

×
Please enable JavaScript in your browser to complete this form.
45174
Home » Antibodies » Ipilimumab

Background of Ipilimumab

Ipilimumab is a fully human IgG1 monoclonal antibody that prevents CTLA-4 on activated T cells from binding to its ligands on antigen-presenting cells, has been shown to increase the percentages of circulating activated CD8 and CD4 T cells and to enhance humoral immunity in patients with advanced melanoma.

Specifications

Catalog NumberKB-1103
Antibody NameIpilimumab
IsotypeHuman IgG1,kappa
TargetCTLA4
Species ReactivityHuman
Host Cell LineEXPI CHO
Purification MethodAffinity purified
Concentration>2 mg/mL
Formulation50 mM sodium citrate,150mM NaCl,pH5.5
Purity>95% by SDS-PAGE and SEC-HPLC
ValidationELISA
Endotoxin Level<0.2 EU/mg as determined by the LAL method
Sterility0.2μm filtered
StorageIt is recommended that the protein should be aliquoted for optimal storage.
Avoid repeated freeze-thaw cycles.
StabilityStable for twelve months from date of receipt when stored at -20°C to -80°C;
Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013 Jul 15;19(14):3977-86.
Please enable JavaScript in your browser to complete this form.